Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study
Aim. To assess the effect of the sodium-glucose transport protein 2 inhibitor empagliflozin on exercise tolerance and left ventricular (LV) diastolic function in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D).Material and methods. The present prospecti...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-02-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849249854907219968 |
|---|---|
| author | A. G. Ovchinnikov A. A. Borisov K. Yu. Zherebchikova O. Yu. Ryabtseva A. D. Gvozdeva V. P. Masenko F. T. Ageev S. A. Boytsov |
| author_facet | A. G. Ovchinnikov A. A. Borisov K. Yu. Zherebchikova O. Yu. Ryabtseva A. D. Gvozdeva V. P. Masenko F. T. Ageev S. A. Boytsov |
| author_sort | A. G. Ovchinnikov |
| collection | DOAJ |
| description | Aim. To assess the effect of the sodium-glucose transport protein 2 inhibitor empagliflozin on exercise tolerance and left ventricular (LV) diastolic function in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D).Material and methods. The present prospective, single-center, open-label study included 60 patients with HFpEF and T2D, who were assigned to groups receiving empagliflozin 10 mg/day. or previously taken hypoglycemic therapy (control group). The follow-up period lasted 24 weeks. All patients underwent a 6-minute walk test and rest and stress echocardiography at baseline and at the end of the study.Results. After 24 weeks. in the empagliflozin group there was an increase in the 6-minute walk test distance by 20 m (95% confidence interval (CI), from 7 to 33 m), a decrease in the early mitral inflow to mitral annulus relaxation velocities (E/e’) ratio by 1,8 (95% CI, from -2,4 to -1,2) and maximum left atrial volume by 2,6 (95% CI, from -4,4 to -0,8) ml/m2, as well as an increase in the diastolic reserve (mitral annulus relaxation velocity increment e’ during exercise increased from 2,2 (95% CI, 1,7 to 2,7) to 3,4 (95% CI, 2,4 to 4,2) cm/s; P<0,01 for all). There were no significant changes in the control group.Conclusion. In patients with HFpEF and T2D, empagliflozin improves exercise tolerance and LV diastolic function. Large-scale placebo-controlled randomized trials are required to prove these findings. |
| format | Article |
| id | doaj-art-941b6979934e4573a7f4a603f0e6cba9 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2021-02-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-941b6979934e4573a7f4a603f0e6cba92025-08-20T03:57:26Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202021-02-0126110.15829/1560-4071-2021-43043150Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center studyA. G. Ovchinnikov0A. A. Borisov1K. Yu. Zherebchikova2O. Yu. Ryabtseva3A. D. Gvozdeva4V. P. Masenko5F. T. Ageev6S. A. Boytsov7National Medical Research Center of Cardiology; Moscow State University of Medicine and DentistryNational Medical Research Center of CardiologyNational Medical Research Center of Cardiology; I.M. Sechenov First Moscow State Medical UniversityNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyAim. To assess the effect of the sodium-glucose transport protein 2 inhibitor empagliflozin on exercise tolerance and left ventricular (LV) diastolic function in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D).Material and methods. The present prospective, single-center, open-label study included 60 patients with HFpEF and T2D, who were assigned to groups receiving empagliflozin 10 mg/day. or previously taken hypoglycemic therapy (control group). The follow-up period lasted 24 weeks. All patients underwent a 6-minute walk test and rest and stress echocardiography at baseline and at the end of the study.Results. After 24 weeks. in the empagliflozin group there was an increase in the 6-minute walk test distance by 20 m (95% confidence interval (CI), from 7 to 33 m), a decrease in the early mitral inflow to mitral annulus relaxation velocities (E/e’) ratio by 1,8 (95% CI, from -2,4 to -1,2) and maximum left atrial volume by 2,6 (95% CI, from -4,4 to -0,8) ml/m2, as well as an increase in the diastolic reserve (mitral annulus relaxation velocity increment e’ during exercise increased from 2,2 (95% CI, 1,7 to 2,7) to 3,4 (95% CI, 2,4 to 4,2) cm/s; P<0,01 for all). There were no significant changes in the control group.Conclusion. In patients with HFpEF and T2D, empagliflozin improves exercise tolerance and LV diastolic function. Large-scale placebo-controlled randomized trials are required to prove these findings.https://russjcardiol.elpub.ru/jour/article/view/4304left ventriclediastolic dysfunctionfilling pressurediastolic stress testheart failure with preserved ejection fractiondiabetesempagliflozin |
| spellingShingle | A. G. Ovchinnikov A. A. Borisov K. Yu. Zherebchikova O. Yu. Ryabtseva A. D. Gvozdeva V. P. Masenko F. T. Ageev S. A. Boytsov Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study Российский кардиологический журнал left ventricle diastolic dysfunction filling pressure diastolic stress test heart failure with preserved ejection fraction diabetes empagliflozin |
| title | Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study |
| title_full | Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study |
| title_fullStr | Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study |
| title_full_unstemmed | Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study |
| title_short | Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study |
| title_sort | effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes a prospective single center study |
| topic | left ventricle diastolic dysfunction filling pressure diastolic stress test heart failure with preserved ejection fraction diabetes empagliflozin |
| url | https://russjcardiol.elpub.ru/jour/article/view/4304 |
| work_keys_str_mv | AT agovchinnikov effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT aaborisov effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT kyuzherebchikova effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT oyuryabtseva effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT adgvozdeva effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT vpmasenko effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT ftageev effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy AT saboytsov effectsofempagliflozinonexercisetoleranceandleftventriculardiastolicfunctioninpatientswithheartfailurewithpreservedejectionfractionandtype2diabetesaprospectivesinglecenterstudy |